This 2002 text defines the field of pharmacogenetics as it applies to psychotropic drugs, for clinicians and researchers.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.
Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
